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Abstract 
Obesity correlates with hematological malignances including leukemias, but risk of specific 
leukemia subtypes like Acute Promyelocytic Leukemia and underlying molecular 
mechanisms are poorly understood. 
We explored multiple datasets for correlation between leukemia, Body Mass Index and 
molecular features. In a population-based study (n=5.2 million), we correlated Body Mass 
Index with promyelocytic, other acute myeloid, lymphoid or other leukemias. In cross-
sectional studies, we tested body mass index deviation in promyelocytic leukemia trial 
cohorts from what expected based on national surveys. We interrogated The Cancer Genome 
Atlas for transcriptional signatures and mutations enriched in promyelocytic leukemia and/or 
obesity and confirmed correlation between body mass and FLT3 mutations in promyelocytic 
leukemia cohorts by logistic regression. 
In the population-based study, Hazard Ratio per 5 kg/m2 increase was: promyelocytic 
leukemia 1.44 (95% CI 1.0-2.08); non-promyelocytic acute myeloid leukemias 1.17 (1.10-
1.26); lymphoid leukemias 1.04 (1.0-1.09); other 1.10 (1.04-1.15). In cross-sectional studies, 
body mass deviated significantly from expected (Italy p<0.001, Spain p=0.011, USA 
p<0.001). Promyelocytic leukemia showed upregulation of polyunsaturated fatty acid 
metabolism genes. Oddds of FLT3 mutations were higher in obese acute myeloid leukemias 
(Odds Ratio=2.4, p=0.007), whether promyelocytic or not, a correlation confirmed in the 
pooled promyelocytic leukemia cohorts (OR 1.22, 1.05-1.43 per 5 kg/m2). 
These results strengthen the evidence for obesity as a bona fide risk factor for myeloid 
leukemias and in particular APL. FLT3 mutations and polyunsaturated fatty acid metabolism 
may play a previously underappreciated role in obesity-associated leukemogenesis. 
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Introduction 
The aetiology of Acute Myeloid Leukemia (AML) remains poorly understood. Genetic 
predisposition or clear exposure to environmental mutagenic agents (smoking, benzene, 
radiation, prior chemotherapy) can be demonstrated only in a minority of cases 1. Age is an 
independent risk factor, probably linked to progressive mutation accumulation and clonal 
stem cell expansion accompanying aging 2. Though obesity has recently emerged as a 
prominent risk factor for a variety of solid tumors3, its impact on hematological neoplasms is 
comparatively less studied. A moderate but consistently positive correlation between body 
mass index (BMI) ad  incidence of leukemias has been identified in observational studies4–6. 
Yet, none of the collected evidence has been considered sufficiently strong to consider obesity 
as a bona fide risk factor for AML 3,7. Most studies did not distinguish between 
myeloid/lymphoid and acute/chronic forms, nor between genetic subtypes within each form. 
AML is recognized as a highly heterogeneous disease with genetically diverse subtypes 8. 
Subtypes have radically different outcomes and, similarly, their risk may be differentially 
affected by environmental factors. Identification of subtype-specific risk associations, 
however, is made difficult by their rarity.   
A genetic subset of AML, Acute Promyelocytic Leukemia (APL), is characterized by a 
specific chromomal translocation (t15;17), homogeneous biology and response to clinical 
agents All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide, which have rendered it the 
most curable form of AML to date9. We previously demonstrated that the risk of relapse after 
ATRA/Idarubicin is significantly increased in overweight/obese APL patients10. In the present 
report, we investigated the association of overweight/obesity with risk of developing APL and 
other leukemias. We describe the results of multiple studies across four Western populations 
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with significantly different dietary regimens and prevalence of obesity. The studies were 
concordant in demonstrating increased risk of developing APL in overweight/obesity 
subjects. In an effort to generate mechanistic hypotheses to explain this relationship, we 
analyzed transcriptomic and mutational data from the AML project in The Cancer Genome 
Atlas (TCGA)11 and identified alterations selectively associated with obesity and/or APL 
which may be involved in obesity-associated leukemogenesis.  
Methods 
Detailed methods are provided as supplementary material 
UK population-based study: data collection and statistical methods 
Methods for the UK population study were described in depth previously 6. The study was 
approved by the London School of Hygiene and Tropical Medicine Ethics Committee. To 
identify outcomes of specific leukaemia sub-types, CPRD clinical records were searched for 
codes relating to specific leukemia subgroups. We controlled for multiple covariates at time 
of the BMI record(s): age, smoking status,; alcohol use, previous diabetes diagnosis, index of 
multiple deprivation, calendar period, and stratified by sex.. We excluded people with missing 
smoking (49 206/5.24 million [0.9%]) and alcohol status (394 196/5.24 million [7.5%]. All 
CIs are presented at the 95% level.  
Cross-sectional studies: data collection and statistical methods 
APL cases from Spain were extracted from the PETHEMA database to include 414 cases 
diagnosed between 1998 and 2012. APL cases from Italy were 134 adult patients treated with 
AIDA protocol included in the previously described cohort 10.  APL cases from USA included 
the entire cohort of the published AML TCGA project 11 (n=20) plus 22 additional APL cases, 
unselected for any clinical variable, diagnosed at Washington University (Expanded TCGA 
cohort). For all case cohorts, BMI was measured at the time of diagnosis. 
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Data collection was approved by the Research Ethics Board of each participating institution, 
as referenced 11–14. Data source for expected BMI in the local population are described in the 
supplementary methods.  
Expression data analysis 
Expression data (RPKM matrix) were downloaded from the AML TCGA data portal. 11. The 
Quantitative Set Analysis for Gene Expression method as implemented in the quSAGE 
package 15 in the R programming language (v 3.2.3) was used to conduct supervised gene set 
enrichment analysis. We focused on the KEGG collection as it is enriched for metabolism-
associated gene annotations16.  
Mutational data analysis 
For the analysis in the TCGA data, mutational data were retrieved from the TCGA AML 
paper11 and AML driver genes (restricted to those with at least 2 mutations in the dataset) 
were downloaded from IntOgen 17.  
For the analysis of the retrospective cohort, FLT3 Internal Tandem Duplication (ITD) 
mutational data were provided by the referring centers.  
Role of the funding source 
Funding sources had no role in study design, collection, analysis, and interpretation of data; 
report writing nor decision to submit the paper for publication 
Results 
Population-based cohort study in the UK 
Overall characteristics of the 5.24 million UK adults included in this study have been 
described previously6. 5.833 subjects with a diagnosis of "leukemia" over the observational 
time were included in the present analysis. These events were further classified in the 
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following groups: "APL" (n=26), "non APL-AML" (n=1.012), lymphoid leukemias ("LL"; 
n=2.823) and "other" (n=1.972). Median time lapse between BMI measurement and diagnosis 
was similar across subgroups (APL: 1,810 days; AML: 2,280 days; LL: 1,928 days; other: 
1,894 days). 
We fit BMI as a three-knot cubic spline and as a linear term. There was no evidence of non-
linearity (p=0.94), suggesting that the relationship was best described by the linear model. 
After adjusting for covariates, per each 5 kg/m2 increase we obtained hazard ratios (HR) of 
1.44 for APL (95% confidence interval (CI) 1.0-2.08), 1.17 for non APL-AML (95% CI 1.10-
1.26), 1.04 for LL (95% CI 1.0-1.09) and 1.10 for other leukemias (95% CI 1.04-1.15) 
(Figure 1 and Table 1). Stratification by gender suggested a stronger effect for male gender in 
APL (HR 1.82, 95% CI 1.10- 3.00 vs female HR 1.19, 95%CI 0.67-1.98), although the 
sample size becomes very small (n=13 each). Together, these results suggest that higher BMI 
is associated with increased risk of all sub-types of leukemia, particularly APL. 
Cross-sectional studies in Italian, Spanish and USA trial cohorts 
Though APL showed the strongest association with higher BMI in the cohort analysis  
described above, results were not conclusive due to the small number of cases identified 
(n=26) and the consequently wide confidence intervals. To strengthen the evidence, we 
carried out retrospective case-control studies using cohorts of APL patients from national 
registries of clinical trials from Spain (PETHEMA) and Italy (GIMEMA) and patients from 
the USA-based AML genome sequencing study (the AML TCGA cohort with 22 additional 
cases characterized at Washington University-St Louis). In all three groups, APL diagnosis 
was established using gold standard diagnostic procedures.  
Demographic characteristics of the three case cohorts (Italy n=134, Spain n=414 and USA 
n=42) are described in Table 2. Gender (female 53.0%, 55.2%, 50% respectively) and age 
(median of 45, 45 and 47 respectively) were similarly represented. Information on ethnicity 
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was unavailable for the Spanish and Italian cohorts, whereas white, black and hispanic 
ethnicities were represented in the USA cohort. 
To generate control groups for comparison, we obtained anthropometric data from 
epidemiological surveys of the general population in the different countries. As the 
prevalence of obesity has increased dramatically in most countries in the last decades 
(especially USA), we obtained data that were as close as possible to the median year of 
diagnosis (2002 for Italy, 2003 for Spain, 2007 for USA) (Table 3 and Methods).  
In all three cohorts, there was strong evidence that the observed BMI distribution for cases 
across WHO BMI classes was different from that expected under the null hypothesis of no 
association (Italy p<0.001, Spain p=0.011, USA p<0.001; Table 3) in gender-, age- and 
ethnicity- (for USA) matched controls. In particular, in all 3 datasets, there were more cases  
than expected in the higher BMI groups, irrespective of gender in all cohorts apart from 
Spain, in which significance was not reached for males (p=0.130), despite a similar trend 
(Table 3). 
Correlation of TCGA transcriptomics data with BMI and AML subtype 
The availability of the TCGA dataset prompted us to search for signatures that could suggest 
a mechanistic rationale for the association between APL and obesity. We interrogated 
available AML transcriptomes with supervised gene set enrichment analysis using quSage 15. 
Focusing on the KEGG gene set collection, APL was associated with increased activity of 13 
and decreased activity of 64 out of 186 gene sets (figure 2A, table 4 and supplementary table 
S1). Intriguingly, among significantly upregulated gene sets we found pathways associated 
with the metabolism of long-chain unsaturated fatty acids (linoleic and arachidonic), which 
are precursors of eicosanoids mediating inflammation-associated cancers18. Also noticeable 
was the APL-associated upregulation of Insulin and Insulin-like Growth Factor (IGF1) 
receptors, but not leptin receptor (figure 2B); insulin signaling-associated pathways were also 
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specifically upregulated in obese vs non-obese APL patients ("type II diabetes mellitus" and 
"insulin signaling", supplementary table S1). 
No pathway was significantly enriched in obese vs non-obese patients among non-M3 cases. 
Correlation of mutational data data with BMI 
We then asked whether obesity is associated with specific driver mutations in AML in the 
TCGA cohort. Out of 23 established driver genes mutated at least twice in the cohort, 
mutations in FLT3 were positively associated with obesity (33/88 obese vs 22/110 non-obese, 
p=0.007, Odds Ratio=2.4, False Discovery Rate (FDR)= 0.16, figure 3 and supplementary 
table S3). When we analysed the two main classes of FLT3 mutations separately (Tyrosine 
Kinase Domain, TKD and Internal Tandem Duplication, ITD), the association held 
statistically significant for ITD (24/88 obese vs 14/110 non-obese, p=0.01, Odds Ratio=2.6) 
but not for TKD (9/88 obese vs 8/110 non-obese, p=0.6). In APL, where all FLT3 mutations 
were ITD, the correlation remained statistically significant (6/12 obese vs 0/8 non-obese, 
p=0.04). In non-APL AMLs, with 32 ITD and 17 TKD, overall FLT3 mutations were still 
significantly enriched in obese patients ((27/49 obese vs 22/102 non-obese, Odds Ratio=2, 
p=0.04) but not when analysed separately (p=0.11 for ITD and 0.44 for TKD).  
We then attempted to validate this finding in the APL cohorts, for which data on FLT3ITD 
(table 5). In the pooled analysis (163 mutated patients / 569 total), OR of having a FLT3 ITD 
was 1.22 (95% CI 1.05-1.43) per each 5 kg/m2 increase. In the individual cohorts, results 
were significant in the Italian (30/114 mutated,  OR 2.35, 95% CI 1.25-4.42) and USA (14/41 
mutated, OR 1.44, 95% CI 0.93-2.24) cohorts, but not in the Spanish (119/414 mutated, OR 
1.09, 95% CI 0.89-1.33).  
Discussion 
In this work we provide substantial evidence for an association between elevated BMI and 
risk of developing AML. The risk was particularly high with the APL subtype,  with an 
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estimated 44% HR increase per each 5 kg/m2. This was qualitatively confirmed by comparing 
expected vs observed BMI distributions in APL cohorts across three western countries (US, 
Spain and Italy) with different obesity prevalence and dietary habits. Additionally, we provide 
hypothesis-generating evidence for molecular mechanisms underlying such association, in 
particular the possible involvement of pro-inflammatory fatty acid metabolism and mutations 
of the tyrosin kinase FLT3. 
Our epidemiological results expand a growing body of literature identifying 
overweight/obesity as a bona fide risk factor for leukemias. The most recent meta-analysis 
reported an adjusted relative risk of 1.14 (95% CI, 1.04–1.26, P = 0.008) for acute myeloid 
leukemias overall5. Despite increasing evidence, the notion of obesity as a risk factor for 
leukemia remains widely overlooked7. Among the highly heterogeneous AML subtypes, APL 
is the most clinically and biologically coherent. We and others previously showed that in 
APL, but not in other AMLs, an elevated BMI significantly affects outcome 10,19. This is also 
in line with the few retrospective studies that have assessed APL as a separate disease entity 
20,21
. No study had addressed this question prospectively, a task made difficult by the rarity of 
the disease but made possible in our case by the very large study population (5.2 million). The 
largest prospective study to date (EPIC), which revealed a statistically significant higher risk 
only in female AMLs, but not in other gender and biological subgroups4, was based on a 
relatively small number of incident cases, only 671 out of 375,021 participants over 11.5 
years of median follow-up. The use of orthogonal epidemiological approaches is a strength of 
the study, as it attempts to mitigate some weaknesses of each design. Registry-based studies 
have little patient selection bias, providing results that are more comparable to real-life 
scenarios. However, the quality of case identification is likely to be sub-optimal; erroneous 
assignment of APL to the general AML ICD code might "deplete" incident cases and further 
reduce statistical power. Case-control studies in the context of clinical trials, on the other 
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hand, offer the advantage of gold-standard diagnosis but might be affected by significant 
patient selection biases. This may have counter-selected obese patients in the present study, 
since the correlated comorbidities may be associated with limited access to clinical trials. 
Another limitation of the study is that we could not provide the same degree of geographical 
homogeneity for control subjects in the case-control studies. This may be particularly relevant 
for the US, known to have ample state-specific differences in BMI distribution. However, this 
variation is mainly due to demographic parameters22, such as age, sex and race, and is 
therefore at least partly accounted for in our multivariate analysis. We also note that our USA 
APL cohort includes a single patient of hispanic ethnicity. Hispanics are considered at higher 
incidence of APL, although some large studies based on Surveillance, Epidemiology, and 
End Results (SEER) data dispute this commonly held conclusion 23  
Understanding the molecular mechanism causing increased cancer risk in obese subjects is 
crucial for adequate nutritional prevention, given the sustained rise of obesity worldwide, 
particularly in emerging economies. The possibility to match transcriptional and mutational 
profiles from TCGA to patient clinical and BMI data provided an opportunity to generate 
hypotheses grounded on actual data. However, extracting biological significance from large 
molecular datasets remains challenging. Shifting analytical focus from single genes to gene 
sets or pathways may allow to capture signals even when the changes affecting individual 
genes are minimal, provided they are coherent. The gene set-based method we employed here 
for transcriptional analysis does not assume equal variances, resulting in improved sensitivity 
and specificity over similar competing methods15. Our main finding is the upregulation of 
several genes involved in the metabolism of pro-inflammatory ω-6 polyunsaturated fatty acids 
(PUFA, linoleic and arachidonic) in APL. These molecules are increased in the plasma of 
metabolically impaired subjects, including the obese24, and may lead to elevated production of 
derivative molecules with multiple effects in signaling and inflammation, enhancing 
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leukemogenesis through several independent  mechanisms: direct growth promotion, 
generation of genotoxic oxidative stress, immune modulation18,25 and generation of 
endogenous agonists for Peroxisome proliferator-activated receptors (PPAR)26. PPARs are 
known insulin sensitizers 27 and their transcriptional targets are upregulated in APL 
(Supplementary Table S2); APL expressed higher levels of insulin and IGF1 receptors and its 
growth may thus be favoured by the increased insulin/IGF1 levels in obese subjects3,28. 
Elevated generation of PUFA-derived eicosanoids by APL cells may also explain the 
association between obesity and ATRA differentiation syndrome (DS) 10, as eicosanoids 
strongly promote leukocyte adhesion and chemokine release in the lungs 29.  
Finally, the association between FLT3 mutations and a higher BMI, although unconfirmed in 
the larger Spanish cohort, is an intriguing finding that we think deserves additional research. 
FLT3 mutations are associated with specific metabolic dependencies which may be 
differentially affected by the systemic nutritional state30. It cannot be entirely ruled out that 
geographical differences in dietary composition may account for the discrepancies in the 
association between BMI and APL risk (weakest in Spain) and FLT3 mutations (null in 
Spain). Consistent with this highly speculative view, a recent EPIC substudy revealed marked 
differences in nutritional patterns between European nations. Despite sharing a theoretical 
propensity for "Mediterranean" diets, Italy and Spain were highly polarized especially in 
terms of average polyunsaturated fatty acid consumption (3 vs 38% of the participants in the 
highest quintile) 31.  
In conclusion, based on evidence provided here, we propose to include obesity among 
environmental factors increasing risk for myeloid neoplasms and in particular APL. 
Additional studies with experimental models will clarify the molecular determinants of this 
relationship and test whether and how specific nutritional components like PUFAs can 
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determine specific mutational and transcriptional alterations able to influence teh natural 
history of the disease. 
 
Declaration  of  interests 
The authors declare no relevant conflict of interest 
References 
1 Mazzarella L, Riva L, Luzi L, Ronchini C, Pelicci PG. The genomic and epigenomic 
landscapes of AML. Semin Hematol. 2014;51(4):259–272. 
2 Shlush LI, Zandi S, Itzkovitz S, Schuh AC. Aging, clonal hematopoiesis and 
preleukemia: not just bad luck? Int J Hematol. 2015;102(5):513–522. 
3 Lauby-Secretan B, Ph D, Scoccianti C, Ph D, Loomis D, Ph D. Body Fatness and 
Cancer — Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–
798. 
4 Saberi Hosnijeh F, Romieu I, Gallo V, et al. Anthropometric characteristics and risk of 
lymphoid and myeloid leukemia in the European Prospective Investigation into Cancer 
and Nutrition (EPIC). Cancer Causes Control. 2013;24(3):427–438. 
5 Li S, Chen L, Jin W, et al. Influence of body mass index on incidence and prognosis of 
acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis. Sci Rep. 
2017;7(1):17998. 
6 Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-
mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 
million UK adults. Lancet. 2014;384(9945):755–765. 
7 American Cancer Society. Leukemia–Acute Myeloid (Myelogenous). 
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-
 14
acute-myeloid-myelogenous-risk-factors. 
8 Komanduri K V, Levine RL. Diagnosis and Therapy of Acute Myeloid Leukemia in 
the Era of Molecular Risk Stratification. Annu Rev Med. 2016;67:59–72. 
9 Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we 
start, where are we now, and the future. Blood Cancer J. 2015;5:e304. 
10 Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk 
of disease relapse and differentiation syndrome in patients with acute promyelocytic 
leukemia treated with the AIDA protocols. Blood. 2012;119(1):49–54. 
11 Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo 
acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. 
12 Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed 
acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 
2011;117(18):4716–4725. 
13 Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic 
leukemia with AIDA induction followed by risk-adapted consolidation for adults 
younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood.  
2010;116(17):3171–3179. 
14 Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic 
leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. 
Blood. 2008;111(3):1078–1084. 
15 Yaari G, Bolen CR, Thakar J, Kleinstein SH. Quantitative set analysis for gene 
expression: A method to quantify gene set differential expression including gene-gene 
correlations. Nucleic Acids Res. 2013;41(18):1–11. 
16 Morishima K, Tanabe M, Furumichi M, Kanehisa M, Sato Y. KEGG: new perspectives 
on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2016;45(D1):D353–
 15
D361. 
17 Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, et al. IntOGen-mutations identifies 
cancer drivers across tumor types. Nat Methods. 2013;10(11):1081-1082. 
18 Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181–193. 
19 Castillo JJ, Mulkey F, Geyer S, et al. Relationship between obesity and clinical 
outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB 
(alliance) clinical trials. Am J Hematol. 2016;91(2):199–204. 
20 Wong O, Harris F, Yiying W, Hua F. A hospital-based case-control study of acute 
myeloid leukemia in Shanghai: Analysis of personal characteristics, lifestyle and 
environmental risk factors by subtypes of the WHO classification. Regul Toxicol 
Pharmacol. 2009;55(3):340–352. 
21 Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between 
increased body mass index and a diagnosis of acute promyelocytic leukemia in patients 
with acute myeloid leukemia. Leukemia. 1997;11(10):1661–1664. 
22 Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the 
distribution of body mass index among US adults, 1999-2010. JAMA. 
2012;307(5):491–497. 
23 Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI. Incidence rates of acute 
promyelocytic leukemia among Hispanics, blacks, Asians,  and non-Hispanic whites in 
the United States. Eur J Cancer Prev. 2006;15(4):367–370. 
24 Caspar-Bauguil S, Fioroni A, Galinier A, et al. Pro-inflammatory phospholipid 
arachidonic acid/eicosapentaenoic acid ratio of dysmetabolic severely obese women. 
Obes Surg. 2012;22(6):935–944. 
25 Trabanelli S, Chevalier MF, Martinez-Usatorre A, et al. Tumour-derived PGD2 and 
NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat 
 16
Commun. 2017;8(1):593. 
26 Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A 
prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and 
promotes adipocyte differentiation. Cell. 1995;83(5):813–819. 
27 Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated 
receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12(3):181–
195. 
28 Poloz Y, Stambolic V. Obesity and cancer, a case for insulin signaling. Cell Death Dis. 
2015;6:e2037. 
29 Dahlén SE, Björk J, Hedqvist P, et al. Leukotrienes promote plasma leakage and 
leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute 
inflammatory response. Proc Natl Acad Sci U S A. 1981;78(6):3887–3891. 
30 Stockard B, Garrett T, Guingab-Cagmat J, Meshinchi S, Lamba J. Distinct Metabolic 
features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid 
Leukemia. Sci Rep. 2018;8(1):5534. 
31 Moskal A, Pisa PT, Ferrari P, et al. Nutrient Patterns and Their Food Sources in an 
International Study Setting: Report from the EPIC Study. PLoS One. 
2014;9(6):e98647. 
  
  
 17
Tables 
 
Table 1. Hazard ratios from the UK population study 
Disease  No. of events  Adjusted HR (per 5kg/m2 increase in BMI) 95% CI 
APL 26 1.44 1.00, 2.08 
AML 1012 1.17 1.10, 1.26  
LL 2823 1.04 1.00, 1.09 
Other 1972 1.10 1.04, 1.15 
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Table 2. Description of the cross-sectional cohorts 
  Italy Spain USA 
  No. 134 No. 414 No. 42 
Age 18 - 35 46 (34.3) 113 (27.3) 13 (31.0) 
 36 - 50 34 (25.4) 145 (35.0) 12 (28.6) 
 51 - 65 40 (29.9) 102 (24.6) 11 (26.2) 
 > 65 14 (10.4) 54 (13.0) 6 (14.3) 
 Median (IQR) 45 (31-57) 45 (34-57) 47 (33-60) 
Gender Male 63 (47.0) 227 (54.8) 21 (50.0) 
 Female 71 (53.0) 187 (45.2) 21 (50.0) 
Year of diagnosis Median (range) 2002 (1997-2010) 2003 (1996-2012) 2007 (2001-2011) 
Race White - - 36 (85.7) 
 Black - - 5 (11.9) 
 Hispanic - - 1 (2.4) 
BMI Median (IQR) 26 (23-28) 26 (23-29) 34 (28-39) 
 
IQR: Interquartile range 
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Table 3. Observed BMI distribution in APL cases and expected BMI distribution in 
general population (percentages in brackets) 
  All Males Females 
Italy BMI Obs Expa P-val Obs Expc P-val Obs Expdc P-val 
 <25.0 48 (35.8) 
77.8 
(58.0) 
<0.001 16 (25.4) 
29.0 
(46.0) 
<0.001 32 (45.1) 
48.8 
(68.7) 
<0.001 
 
25.0-
29.9 
71 (53.0) 
44.8 
(33.4) 
 42 (66.7) 
28.0 
(44.5) 
 29 (40.8) 
16.8 
(23.6) 
 
 >=30.0 15 (11.2) 11.4 (8.5)  5 (7.9) 6.0 (9.5)  10 (14.1) 5.5 (7.7)  
 Total 134 134  63 63  71 71  
Spain BMI Obs Expa P-val Obs Expc P-val Obs Expdc P-val 
 <25.0 
172 
(41.5) 
189.9 
(45.9) 
0.011 79 (34.8) 
85.0 
(37.4) 
0.130 93 (49.7) 
104.9 
(56.1) 
0.033 
 
25.0-
29.9 
156 
(37.7) 
158.1 
(38.2) 
 99 (43.6) 
103.2 
(45.5) 
 57 (30.5) 
55.9 
(29.4) 
 
 >=30.0 86 (20.8) 
66.0 
(15.9) 
 49 (21.6) 
38.8 
(17.1) 
 37 (19.8) 
27.2 
(14.6) 
 
 Total 414 414  227 227  187 187  
USA BMI Obs Expb P-val Obs Expc P-val Obs Expdd P-val 
 <25.0 2 (4.8) 
12.8 
(30.6) 
<0.001 1 (4.8) 5.3 (25.4) 0.002 1 (4.8) 7.5 (35.7) 0.003 
 
25.0-
29.9 
13 (31.0) 
13.7 
(32.6) 
 5 (23.8) 7.9 (37.7)  8 (38.1) 5.8 (27.6)  
 
30.0-
34.9 
12 (28.6) 8.6 (20.5)  9 (42.9) 4.8 (23.0)  3 (14.3) 3.8 (18.0)  
 >=35.0 15 (35.7) 6.9 (16.3)  6 (28.6) 2.9 (13.9)  9 (42.9) 3.9 (18.8)  
 Total 42 42  21 21  21 21  
Expected frequencies were obtained from the BMI distribution in the general population of 
the area of the APL cases, period of APL diagnosis and in addition: aage class and sex; bage 
class, sex and race; cage class; dage class and race.  
  
 20
Table 4. Significantly upregulated KEGG pathways in APL vs AML in TCGA 
pathway.name log.fold.cha
nge 
p.Value FDR 
KEGG_RENIN_ANGIOTENSIN_SYSTEM 0.6503 0.0023 0.0093 
KEGG_LINOLEIC_ACID_METABOLISM 0.6381 0.0002 0.0010 
KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_
HEPARAN_SULFATE 
0.4217 0.0000 0.0000 
KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LA
CTO_AND_NEOLACTO_SERIES 
0.3391 0.0003 0.0017 
KEGG_ALANINE_ASPARTATE_AND_GLUTAMAT
E_METABOLISM 
0.3258 0.0009 0.0039 
KEGG_ARACHIDONIC_ACID_METABOLISM 0.3221 0.0037 0.0130 
KEGG_GLYCOSAMINOGLYCAN_DEGRADATION 0.3208 0.0000 0.0001 
KEGG_HISTIDINE_METABOLISM 0.2996 0.0044 0.0148 
KEGG_ARGININE_AND_PROLINE_METABOLISM 0.2582 0.0001 0.0008 
KEGG_LIMONENE_AND_PINENE_DEGRADATION 0.1662 0.0087 0.0250 
KEGG_CARDIAC_MUSCLE_CONTRACTION 0.1475 0.0084 0.0245 
KEGG_PROTEIN_EXPORT 0.1439 0.0066 0.0204 
KEGG_PATHWAYS_IN_CANCER 0.1346 0.0169 0.0428 
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Table 5. Logistic regression of BMI and FLT3 ITD mutations 
BMI All 3 cohorts 
163/569a 
ITALY 
30/114a 
SPAIN 
119/414a 
USA 
14/41a 
 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
 
    
5 unit increase 1.22 (1.05-1.43) 2.35 (1.25-
4.42) 
1.09 (0.89-
1.33) 
1.44 (0.93-
2.24) 
     
≥ 25 vs <25b - 4.40 (1.63-
11.9) 
1.15 (0.75-
1.78) 
- 
≥ 30 vs <30b - - - 6.46 (1.21-
34.5) 
 
a Mutations / All patients; b Given the small number of obese patients in Italy and Spain, we compared 
overweight/obese patients versus normal weight patients (i.e. BMI ≥ 25 vs <25). Given the small number of 
normal weight patients in USA, we compared obese patients versus non-obese patients (i.e. BMI ≥ 30 vs <30).  
 
Figure Legends 
 
Fig 1: relationship between BMI and log-hazard ratio (HR) for leukemias in the UK population. (A) APL;  
(B) other AMLs; (C) lymphoid leukemias; (D) all leukemias. Mean (dark line) ± 95% confidence intervals 
(shaded area) is plotted. 
Fig 2: Differential activities of KEGG pathways and insulin/leptin receptors in the M3 vs non M3 quSage 
comparison in the TCGA. (A) Activity score with 95% CI of 186 KEGG gene sets; significant gene sets are 
color-coded in red (if upregulated) or green (if downregulated) (B) Insulin/IGF1 receptor pathway and leptin 
receptors. Mean ± 95% confidence interval are plotted 
Fig 3. Association between obesity and FLT3 mutations. (A) Bubble plot representing odds ratio vs -logP 
value of any mutation in 23 driver genes in the TCGA AML cohort. FLT3 (in red) is the only gene with False 
Discovery Rate < 0.25. Bubble size reflects the number of obese patients with a mutation. Data are tabulated in 
supplementary table S3 
 



Supplementary methods 
UK population-based study: data collection and statistical methods 
Methods for the UK population study were described in depth previously 1. The study was approved by the London School of Hygiene and 
Tropical Medicine Ethics Committee.  Briefly, data were collected from the UK Clinical Practice Research Datalink (CPRD), which contains 
computerised primary-care records from general practitioners who use the Vision IT system and have agreed at the practice level to participate 
(covering about 9% of the UK population). The CPRD dataset is representative of the UK population in terms of age, sex, ethnicity and BMI 
when compared with census data 2,3 Study entry began 12 months after registration and we assigned BMI records as exposure only 12 months 
after their recording, to guard against reverse causality (ie, BMI being affected by undiagnosed cancer). We included all people aged 16 years or 
older with BMI and subsequent eligible follow-up time. BMI was recorded as per local general practice. Individuals with any record of cancer 
before study entry were excluded. BMI records and diagnosis collected between years 1987-2012	were	included	in	the	analysis.	To identify 
outcomes of specific leukaemia sub-types, CPRD clinical records were searched for codes relating to: AML (ICD-10 codes: C92.0, C92.5, 
C92.6, C93.0, C94.0, C95.0); APL (ICD-10 code C92.4); LL (ICD-10 code C91); and any other leukaemias that were not specifically coded 
("other").  
Subjects were followed-up from study entry until the earliest of: first cancer diagnoses (any site), death, transfer out of CPRD, or last data 
collection of the practice. To relate BMI to risk of each type of leukaemia, we fitted Cox regression models with attained age as the underlying 
timescale. We fitted fully adjusted models, with BMI as a continuous linear term to estimate the average effect of a 5 kg/m² increase in BMI on 
leukaemia risk. We also fitted a model including BMI as a 3-knot spline in case of non-linearity in the relationship with leukaemia risk; we 
tested for evidence of non-linearity by conducting a likelihood ratio test comparing nested models with and without the non-linear terms in the 
spline basis. We controlled for the following covariates at time of the BMI record(s): age (three-knot restricted cubic spline to allow for non-
linearity); smoking status (never smoker, current smoker, ex-smoker); alcohol use (non-drinker, current drinker [light, moderate, heavy, 
unknown], ex-drinker); previous diabetes diagnosis; index of multiple deprivation (in quintiles, a measure of socioeconomic status); calendar 
period (<1989, 1990–94, 1995–99, 2000–04, 2005–09, ≥2010); and stratified by sex. We excluded people with missing smoking (49 206/5.24 
million [0.9%]) and alcohol status (394 196/5.24 million [7.5%]. All CIs are presented at the 95% level.  
Cross-sectional studies: data collection and statistical methods 
APL cases from Spain were extracted from the PETHEMA database to include 414 cases diagnosed between 1998 and 2012. APL cases from 
Italy were 134 adult patients treated with AIDA protocol included in the previously described cohort 4.  APL cases from USA included the entire 
cohort of the published AML TCGA project 5 (n=20) plus 22 additional APL cases, unselected for any clinical variable, diagnosed at 
Washington University (Expanded TCGA cohort). For all case cohorts, BMI was measured at the time of diagnosis. Data collection was 
approved by the Research Ethics Board of each participating institution, as referenced 5–8 
We compared the distribution of BMI observed in the three APL case cohorts to the distribution of BMI expected in the general population of 
the same countries. Specifically, to calculate the expected distribution of BMI in Italy we used data from the Italian National Institute of 
Statistics 9 and we selected the area of Lazio, where the APL cases were diagnosed, in the years 2000-2010. For Spain, we used data from the 
Eurostat 10 and we selected the general population of Spain in the year 2008, the only year available. For both Italy and Spain, the expected BMI 
distribution was calculated using the available age- and sex- specific BMI distribution of the general population classified in 3 categories (<25; 
25-29.9; ≥30). For USA we used the 2009-2010 data from the American National Health and Nutrition Examination Survey 11. The expected 
BMI distribution was calculated using the available race-, age- and sex- specific BMI distribution of the general population classified in 4 
categories (<25; 25-29.9; 30.0-34.9; ≥35). 
The global null hypothesis that the observed counts did not differ from the expected ones across the BMI categories was tested in a null Poisson 
regression model, where the observed counts were considered as dependent variable and the expected counts as the offset. We included in the 
model BMI as an ordinal variable to test the log-linear relationship between BMI and the observed to expected ratio (i.e. to test for linear trend). 
The Pearson's chi-square goodness of fit test p-value was reported. 
Expression data analysis 
Expression data (RPKM matrix) were downloaded from the AML TCGA data portal. Cases with available RNAseq, BMI and FAB classification 
data (177/200) were used in the present study. Cases were classified by FAB in "APL" (FAB="M3") and "non-APL" (FAB ≠ "M3") and by BMI 
in "obese" (BMI ≥ 30) and "non-obese" (BMI < 30). Genes with < 0.2 RPKM in at least 75% of patients were removed 5. The Quantitative Set 
Analysis for Gene Expression method as implemented in the quSAGE package 12 in the R programming language (v 3.2.3) was used to conduct 
supervised gene set enrichment analysis. For each expressed gene, the quSAGE algorithm calculates a probability density function (PDF) of 
differential expression between two groups of samples. For each gene set, it then calculates "activity", ie the mean difference in log-
expression of individual genes included in a gene set. Gene sets with False Discovery Rate (FDR) < 0.05 were considered significant. We 
focused on the KEGG and CGP gene set collections, downladed from MSigDB (http://software.broadinstitute.org/gsea/msigdb/). The CGP 
collection was used to confirm enrichment of previously identified APL-specific gene signatures 13 (supplementary table S2). We focused on the 
KEGG collection as it is enriched for metabolism-associated gene annotations14. The script to generate the present results is available upon 
request.  
Mutational data analysis 
For the analysis in the TCGA data, mutational data were retrieved from the TCGA AML paper5 and AML driver genes were downloaded from 
IntOgen 15. For each gene, different mutations were conflated so that gene status in each patient was either "mutated" or "wild type". For each 
gene we then calculated the number of mutated or wild-type patients in the obese or non-obese groups, and calculated Odds Ratios (OR), 95% 
confidence intervals (CI) and p-values by Fisher's test with Benjamini-Hochberg correction. Only genes with >1 mutation in the dataset were 
considered, using the fdsm package in R. 
For the analysis of the retrospective cohort, FLT3 Internal Tandem Duplication (ITD) mutational data were provided by the referring centers. 
Logistic regression was employed to calculate ORs with 95% CI. 
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 Table	S1.	quSage	activity	scores	of	KEGG	gene	sets.	Only	gene	sets	with	FDR	<	0.05	in	at	least	one	comparison	are	shown			 M3vsNonM3.KEGG		 ObVSNorm_All.KEGG		 ObVSNorm_M3.KEGG		 ObVSNorm_nonM3.K	EGG		pathway.name		 	log.fold.c	hange		 	p.V	alue		 	FD	R				 log.fold.c	hange		 	p.V	alue		 	 	FD	R		 log.fold.c	hange		 	p.V	alue		 	 	FD	R		 log.fold.c	hange		 	p.V	alue		 	 	FD	R		KEGG_RENIN_ANGIOTENSIN_SYSTEM		 0.6503		 0.0	023		 0.0	09	3		 -0.0187		 0.8	880		 0.9	85	9		 -0.2661		 0.5	992		 0.6	94	3		 -0.0294		 0.8	297		 0.9	90	1		KEGG_LINOLEIC_ACID_METABOLISM		 	0.6381		 	0.0	002		 	0.0	01	0		 0.0537		 	0.6	317		 	 	0.9	85	9		 0.1104		 	0.6	912		 	 	0.7	60	7		 0.0136		 	0.9	083		 	 	0.9	90	1		KEGG_GLYCOSAMINOGLYCAN_BIOSYN	THESIS_HEPARAN_SULFATE		 0.4217		 0.0	000		 	0.0	00	0		 0.1973		 0.0	022		 0.4	09	8		 0.2753		 0.1	104		 0.2	23	3		 0.1680		 0.0	122		 0.9	90	1		KEGG_GLYCOSPHINGOLIPID_BIOSYNT	HESIS_LACTO_AND_NEOLACTO_SERIES		 0.3391		 0.0	003		 0.0	01	7		 0.0490		 0.4	612		 0.9	85	9		 0.0944		 0.5	590		 0.6	64	1		 0.0264		 0.7	106		 0.9	90	1		KEGG_ALANINE_ASPARTATE_AND_GL	UTAMATE_METABOLISM		 0.3258		 0.0	009		 0.0	03	9		 0.0366		 0.5	529		 0.9	85	9		 0.2905		 0.1	212		 0.2	37	2		 -0.0065		 0.9	168		 0.9	90	1		KEGG_ARACHIDONIC_ACID_METABOLI	SM		 	0.3221		 	0.0	037		 	0.0	13	0		 0.0907		 	0.2	234		 	 	0.9	85	9		 0.0785		 	0.6	402		 	 	0.7	26	4		 0.0751		 	0.3	437		 	 	0.9	90	1			KEGG_GLYCOSAMINOGLYCAN_DEGRA	DATION		 0.3208		 0.0	000		 0.0	00		 0.1114		 0.0	519		 0.9	85		 -0.0164		 0.9	407		 0.9	50		 0.1077		 0.0	707		 0.9	90			 		 		 	1				 	 		 9			 		 	 		 9			 		 	 		 1			 		KEGG_HISTIDINE_METABOLISM		 0.2996		 0.0	044		 0.0	14	8		 0.0633		 0.3	112		 0.9	85	9		 0.1274		 0.4	197		 0.5	47	5		 0.0410		 0.5	403		 0.9	90	1		
KEGG_ARGININE_AND_PROLINE_META	BOLISM		 0.2582				 0.0	001				
	0.0	00	8				 -0.0136		
0.7	768				 0.9	85	9			 		 0.1283		 0.2	240				 0.3	65	5			 		 -0.0421		 0.4	087				 0.9	90	1			 		KEGG_LIMONENE_AND_PINENE_DEGR	ADATION		 0.1662		 0.0	087		 0.0	25	0		 0.0088		 0.8	790		 0.9	85	9		 0.0364		 0.7	788		 0.8	13	8		 -0.0030		 0.9	581		 0.9	90	1		KEGG_CARDIAC_MUSCLE_CONTRACTIO	N		 	0.1475		 	0.0	 	0.0	 0.0321		 	0.4	 	 	0.9	 0.1541		 	0.0	 	 	0.1	 0.0120		 	0.7	 	 	0.9	
084		 24	5		 163		 85	9		 864		 98	5		 777		 90	1		KEGG_PROTEIN_EXPORT		 0.1439		 0.0	066		 	0.0	20	4		 -0.0374		 0.2	974		 0.9	85	9		 0.1933		 0.0	958		 0.2	03	1		 -0.0688		 0.0	632		 0.9	90	1		KEGG_PATHWAYS_IN_CANCER		 	0.1346		 	0.0	169		 	0.0	42	8		 0.0002		 	0.9	991		 	 	0.9	99	1		 0.2432		 	0.0	112		 	 	0.0	92	2		 -0.0316		 	0.4	585		 	 	0.9	90	1		KEGG_UBIQUITIN_MEDIATED_PROTEO	LYSIS		 -0.0801		 0.0	163		 0.0	42	5		 -0.0111		 0.6	109		 0.9	85	9		 0.1777		 0.0	128		 0.0	92	2		 -0.0258		 0.2	492		 0.9	90	1		KEGG_PANCREATIC_CANCER		 	-0.0866		 	0.0	187		 	0.0	46	3		 -0.0124		 	0.6	339		 	 	0.9	85	9		 0.1224		 	0.0	993		 	 	0.2	07	4		 -0.0213		 	0.4	381		 	 	0.9	90	1		KEGG_INSULIN_SIGNALING_PATHWAY		 -0.0874		 0.0	170		 0.0	42	8		 0.0096		 0.7	116		 0.9	85	9		 0.1847		 0.0	012		 0.0	40	2		 -0.0031		 0.9	115		 0.9	90	1		KEGG_PYRIMIDINE_METABOLISM		 -0.0975		 0.0	165		 	0.0	42	5		 0.0062		 0.8	245		 0.9	85	9		 0.0774		 0.3	112		 0.4	63	1		 0.0043		 0.8	807		 0.9	90	1		KEGG_RNA_DEGRADATION		 	-0.1018		 	0.0	146		 	0.0	39	5		 -0.0229		 	0.4	004		 	 	0.9	85	9		 0.1292		 	0.1	580		 	 	0.2	80	1		 -0.0329		 	0.2	515		 	 	0.9	90	1		KEGG_AMYOTROPHIC_LATERAL_SCLE	ROSIS_ALS		 	-0.1077		 	0.0	002		 	0.0	01	3		 0.0147		 	0.5	221		 	 	0.9	85	9		 0.0734		 	0.2	217		 	 	0.3	65	5		 0.0147		 	0.5	431		 	 	0.9	90	1		KEGG_NON_SMALL_CELL_LUNG_CANCE	R		 	-0.1128		 	0.0	010		 	0.0	04	2		 0.0152		 	0.5	572		 	 	0.9	85	9		 0.1381		 	0.0	261		 	 	0.1	03	4		 0.0090		 	0.7	385		 	 	0.9	90	1		KEGG_CHRONIC_MYELOID_LEUKEMIA		 	-0.1140		 	0.0	001		 	0.0	00	9		 0.0155		 	0.4	669		 	 	0.9	85	9		 0.2026		 	0.0	126		 	 	0.0	92	2		 0.0030		 	0.8	915		 	 	0.9	90	1		KEGG_COLORECTAL_CANCER		 	-0.1163		 	0.0	002		 	0.0	01	0		 0.0126		 	0.5	758		 	 	0.9	85	9		 0.2530		 	0.0	000		 	 	0.0	01	0		 -0.0052		 	0.8	215		 	 	0.9	90	1		KEGG_PEROXISOME		 -0.1242		 0.0	125		 0.0	34	2		 0.0283		 0.4	070		 0.9	85	9		 0.1403		 0.1	243		 0.2	40	8		 0.0241		 0.5	087		 0.9	90	1		KEGG_APOPTOSIS		 -0.1347		 0.0	008		 0.0	03	8		 0.0364		 0.1	948		 0.9	85	9		 0.1970		 0.0	187		 0.1	03	4		 0.0279		 0.3	395		 0.9	90	1		KEGG_PROTEASOME		 	-0.1371		 	0.0	 	0.0	 -0.0334		 	0.2	 	 	0.9	 0.1156		 	0.2	 	 	0.3	 -0.0412		 	0.2	 	 	0.9	
013		 05	3		 960		 85	9		 150		 63	5		 221		 90	1			KEGG_REGULATION_OF_ACTIN_CYTOS	KELETON				 -0.1426		 0.0	154		 0.0	40		 -0.0296		 0.4	645		 0.9	85		 0.1678		 0.0	559		 0.1	53		 -0.0419		 0.3	333		 0.9	90			 		 		 	9				 	 		 9			 		 	 		 3			 		 	 		 1			 		KEGG_PHOSPHATIDYLINOSITOL_SIGN	ALING_SYSTEM		 -0.1478		 0.0	024		 0.0	09	4		 0.0232		 0.4	947		 0.9	85	9		 0.1730		 0.0	077		 0.0	92	2		 0.0164		 0.6	496		 0.9	90	1		
KEGG_LONG_TERM_POTENTIATION		 -0.1525				 0.0	053				
	0.0	17	4				 -0.0171		
0.6	000				 0.9	85	9			 		 0.1396		 0.0	108				 0.0	92	2			 		 -0.0247		 0.4	774				 0.9	90	1			 		KEGG_VALINE_LEUCINE_AND_ISOLEUC	INE_DEGRADATION		 -0.1664		 0.0	021		 0.0	08	5		 -0.0054		 0.8	847		 0.9	85	9		 0.1395		 0.3	371		 0.4	86	0		 -0.0109		 0.7	775		 0.9	90	1		KEGG_PENTOSE_PHOSPHATE_PATHW	AY		 	-0.1698		 	0.0	029		 	0.0	10	5		 -0.0559		 	0.1	519		 	 	0.9	85	9		 -0.0887		 	0.2	304		 	 	0.3	72	6		 -0.0438		 	0.2	926		 	 	0.9	90	1		KEGG_PATHOGENIC_ESCHERICHIA_CO	LI_INFECTION		 -0.1747		 0.0	028		 	0.0	10	5		 0.0001		 0.9	983		 0.9	99	1		 0.2391		 0.0	248		 0.1	03	4		 -0.0145		 0.7	640		 0.9	90	1		KEGG_WNT_SIGNALING_PATHWAY		 	-0.1798		 	0.0	003		 	0.0	01	8		 -0.0202		 	0.5	735		 	 	0.9	85	9		 0.2704		 	0.0	049		 	 	0.0	79	8		 -0.0399		 	0.2	867		 	 	0.9	90	1		KEGG_MELANOGENESIS		 -0.1822		 0.0	101		 0.0	28	5		 0.0017		 0.9	737		 0.9	99	1		 0.2365		 0.0	708		 0.1	72	8		 -0.0120		 0.8	199		 0.9	90	1		KEGG_ENDOMETRIAL_CANCER		 	-0.1884		 	0.0	002		 	0.0	01	1		 0.0121		 	0.7	239		 	 	0.9	85	9		 0.1965		 	0.0	107		 	 	0.0	92	2		 0.0039		 	0.9	124		 	 	0.9	90	1		KEGG_MISMATCH_REPAIR		 -0.1993		 0.0	191		 0.0	46	8		 -0.0195		 0.7	019		 0.9	85	9		 0.3508		 0.0	325		 0.1	08	0		 -0.0461		 0.3	817		 0.9	90	1		KEGG_RIBOFLAVIN_METABOLISM		 -0.2067		 0.0	027		 	0.0	10	2		 -0.0038		 0.9	237		 0.9	87	4		 0.0432		 0.6	998		 0.7	65	7		 0.0027		 0.9	527		 0.9	90	1		KEGG_DNA_REPLICATION		 	-0.2114		 	0.0	206		 	0.0	49	6		 -0.0159		 	0.7	776		 	 	0.9	85	9		 0.2973		 	0.0	941		 	 	0.2	03	1		 -0.0361		 	0.5	441		 	 	0.9	90	1		KEGG_JAK_STAT_SIGNALING_PATHWA	Y		 	 	 	 0.0150		 	 	 	 0.2723		 	 	 	 0.0008		 	 	 	
-0.2119		 0.0	084		 0.0	24	5		 0.7	826		 0.9	85	9		 0.0	166		 0.1	01	5		 0.9	909		 0.9	91	8		KEGG_DORSO_VENTRAL_AXIS_FORMA	TION		 	-0.2122		 	0.0	045		 	0.0	14	9		 0.0181		 	0.7	070		 	 	0.9	85	9		 0.2959		 	0.0	227		 	 	0.1	03	4		 0.0018		 	0.9	728		 	 	0.9	91	8		KEGG_INOSITOL_PHOSPHATE_METAB	OLISM		 	-0.2128		 	0.0	000		 	0.0	00	2		 -0.0010		 	0.9	730		 	 	0.9	99	1		 0.1404		 	0.0	113		 	 	0.0	92	2		 -0.0037		 	0.9	133		 	 	0.9	90	1		KEGG_EPITHELIAL_CELL_SIGNALING_I	N_HELICOBACTER_PYLORI_INFECTION		 	-0.2133		 	0.0	000		 	0.0	00	1		 0.0413		 	0.2	478		 	 	0.9	85	9		 0.1706		 	0.0	797		 	 	0.1	85	3		 0.0403		 	0.2	762		 	 	0.9	90	1		KEGG_RIG_I_LIKE_RECEPTOR_SIGNALI	NG_PATHWAY		 -0.2148		 0.0	006		 0.0	02	7		 0.0316		 0.3	340		 0.9	85	9		 0.1770		 0.1	163		 0.2	32	5		 0.0289		 0.3	786		 0.9	90	1		KEGG_LONG_TERM_DEPRESSION		 -0.2202		 0.0	068		 0.0	20	7		 -0.0218		 0.6	805		 0.9	85	9		 0.1495		 0.0	884		 0.2	00	5		 -0.0272		 0.6	329		 0.9	90	1		KEGG_BETA_ALANINE_METABOLISM		 	-0.2380		 	0.0	059		 	0.0	19	0		 -0.0296		 	0.5	572		 	 	0.9	85	9		 0.1582		 	0.4	291		 	 	0.5	50	4		 -0.0358		 	0.4	898		 	 	0.9	90	1			KEGG_FRUCTOSE_AND_MANNOSE_ME	TABOLISM				 -0.2433		 0.0	000		 0.0	00		 -0.0113		 0.7	895		 0.9	85		 0.1312		 0.0	715		 0.1	72		 -0.0124		 0.7	805		 0.9	90			 		 		 	1				 	 		 9			 		 	 		 8			 		 	 		 1			 		KEGG_DRUG_METABOLISM_OTHER_EN	ZYMES		 -0.2535		 0.0	082		 0.0	24	5		 0.0270		 0.6	671		 0.9	85	9		 -0.1247		 0.5	606		 0.6	64	1		 0.0563		 0.3	928		 0.9	90	1		
KEGG_O_GLYCAN_BIOSYNTHESIS		 -0.2725				 0.0	103				
	0.0	28	6				 0.0280		
0.6	628				 0.9	85	9			 		 0.4616		 0.0	169				 0.1	01	5			 		 -0.0006		 0.9	918				 0.9	91	8			 		KEGG_CALCIUM_SIGNALING_PATHWA	Y		 -0.2771		 0.0	001		 0.0	00	4		 -0.0054		 0.9	034		 0.9	85	9		 0.2483		 0.0	677		 0.1	70	2		 -0.0159		 0.7	335		 0.9	90	1		KEGG_VALINE_LEUCINE_AND_ISOLEUC	INE_BIOSYNTHESIS		 	-0.2834		 	0.0	044		 	0.0	14	8		 0.0075		 	0.8	942		 	 	0.9	85	9		 0.2955		 	0.1	340		 	 	0.2	51	8		 -0.0060		 	0.9	138		 	 	0.9	90	1		KEGG_NOD_LIKE_RECEPTOR_SIGNALIN	G_PATHWAY		 -0.2899		 0.0	002		 	0.0	01	0		 0.0682		 0.1	886		 0.9	85	9		 0.2244		 0.0	358		 0.1	12	8		 0.0688		 0.2	078		 0.9	90	1		
KEGG_CYTOSOLIC_DNA_SENSING_PAT	HWAY		 	-0.3003		 	0.0	000		 	0.0	00	1		 0.0227		 	0.5	065		 	 	0.9	85	9		 0.1045		 	0.3	320		 	 	0.4	86	0		 0.0310		 	0.3	465		 	 	0.9	90	1		KEGG_B_CELL_RECEPTOR_SIGNALING_	PATHWAY		 -0.3036		 0.0	000		 0.0	00	0		 0.0131		 0.7	092		 0.9	85	9		 0.2192		 0.0	125		 0.0	92	2		 0.0090		 0.7	968		 0.9	90	1		KEGG_ERBB_SIGNALING_PATHWAY		 	-0.3255		 	0.0	000		 	0.0	00	0		 0.0105		 	0.7	342		 	 	0.9	85	9		 0.2496		 	0.0	011		 	 	0.0	40	2		 0.0043		 	0.8	823		 	 	0.9	90	1		KEGG_GLYCEROLIPID_METABOLISM		 -0.3303		 0.0	001		 0.0	00	4		 -0.0405		 0.4	091		 0.9	85	9		 0.2382		 0.0	564		 0.1	53	3		 -0.0509		 0.3	134		 0.9	90	1		KEGG_FC_GAMMA_R_MEDIATED_PHAG	OCYTOSIS		 -0.3306		 0.0	000		 	0.0	00	0		 -0.0166		 0.7	137		 0.9	85	9		 0.1495		 0.0	525		 0.1	50	3		 -0.0154		 0.7	414		 0.9	90	1		KEGG_SPHINGOLIPID_METABOLISM		 	-0.3680		 	0.0	000		 	0.0	00	0		 0.0174		 	0.6	685		 	 	0.9	85	9		 0.3152		 	0.0	416		 	 	0.1	24	8		 0.0076		 	0.8	462		 	 	0.9	90	1		KEGG_RETINOL_METABOLISM		 	-0.3804		 	0.0	029		 	0.0	10	5		 0.0302		 	0.7	095		 	 	0.9	85	9		 0.0697		 	0.7	325		 	 	0.7	92	1		 0.0472		 	0.5	811		 	 	0.9	90	1		KEGG_GAP_JUNCTION		 	-0.4063		 	0.0	000		 	0.0	00	1		 -0.0223		 	0.6	911		 	 	0.9	85	9		 0.3313		 	0.0	358		 	 	0.1	12	8		 -0.0360		 	0.5	254		 	 	0.9	90	1		KEGG_CELL_ADHESION_MOLECULES_C	AMS		 	-0.4328		 	0.0	008		 	0.0	03	5		 0.0313		 	0.7	135		 	 	0.9	85	9		 0.5266		 	0.0	280		 	 	0.1	03	4		 0.0053		 	0.9	546		 	 	0.9	90	1		KEGG_NON_HOMOLOGOUS_END_JOINI	NG		 	-0.4837		 	0.0	005		 	0.0	02	6		 0.0143		 	0.8	625		 	 	0.9	85	9		 0.4767		 	0.0	342		 	 	0.1	11	5		 -0.0058		 	0.9	434		 	 	0.9	90	1		KEGG_TOLL_LIKE_RECEPTOR_SIGNALI	NG_PATHWAY		 -0.4982		 0.0	000		 0.0	00	0		 0.0443		 0.4	457		 0.9	85	9		 0.3124		 0.0	205		 0.1	03	4		 0.0448		 0.4	386		 0.9	90	1		KEGG_OLFACTORY_TRANSDUCTION		 -0.5325		 0.0	062		 0.0	19	7		 0.1045		 0.4	100		 0.9	85	9		 0.1150		 0.7	770		 0.8	13	8		 0.1333		 0.3	200		 0.9	90	1		KEGG_CHEMOKINE_SIGNALING_PATH	WAY		 	-0.5333		 	0.0	000		 	0.0	00	0		 -0.0104		 	0.8	722		 	 	0.9	85	9		 0.1242		 	0.4	531		 	 	0.5	69	4		 0.0050		 	0.9	422		 	 	0.9	90	1			KEGG_PENTOSE_AND_GLUCURONATE_	INTERCONVERSIONS		 -0.6093		 0.0	010		 0.0	04		 0.0156		 0.8	942		 0.9	85		 -0.1942		 0.5	218		 0.6	32		 0.0700		 0.5	586		 0.9	90		
			 		 		 	2				 	 		 9			 		 	 		 0			 		 	 		 1			 		KEGG_BIOSYNTHESIS_OF_UNSATURAT	ED_FATTY_ACIDS		 -0.6717		 0.0	000		 0.0	00	0		 -0.0434		 0.5	171		 0.9	85	9		 0.4095		 0.0	304		 0.1	06	2		 -0.0528		 0.4	121		 0.9	90	1		
KEGG_VIRAL_MYOCARDITIS		 -0.6738				 0.0	000				
	0.0	00	0				 -0.0105		
0.8	928				 0.9	85	9			 		 0.3705		 0.0	201				 0.1	03	4			 		 -0.0122		 0.8	761				 0.9	90	1			 		KEGG_ANTIGEN_PROCESSING_AND_PR	ESENTATION		 -0.6982		 0.0	000		 0.0	00	0		 0.0580		 0.5	438		 0.9	85	9		 0.4852		 0.0	123		 0.0	92	2		 0.0535		 0.5	840		 0.9	90	1		KEGG_SYSTEMIC_LUPUS_ERYTHEMAT	OSUS		 	-0.7637		 	0.0	000		 	0.0	00	1		 0.0663		 	0.5	374		 	 	0.9	85	9		 0.1498		 	0.6	639		 	 	0.7	48	4		 0.1000		 	0.3	574		 	 	0.9	90	1		KEGG_LEISHMANIA_INFECTION		 -0.7943		 0.0	000		 	0.0	00	0		 0.0247		 0.7	869		 0.9	85	9		 0.2493		 0.1	456		 0.2	66	7		 0.0455		 0.6	214		 0.9	90	1		KEGG_PRIMARY_BILE_ACID_BIOSYNTH	ESIS		 	-0.8093		 	0.0	000		 	0.0	00	0		 -0.0140		 	0.8	994		 	 	0.9	85	9		 0.0694		 	0.8	325		 	 	0.8	50	8		 0.0216		 	0.8	437		 	 	0.9	90	1		KEGG_GRAFT_VERSUS_HOST_DISEASE		 -0.9436		 0.0	000		 0.0	00	1		 0.1202		 0.3	917		 0.9	85	9		 0.7427		 0.0	248		 0.1	03	4		 0.1099		 0.4	481		 0.9	90	1		KEGG_TYPE_I_DIABETES_MELLITUS		 	-0.9923		 	0.0	000		 	0.0	00	0		 0.0923		 	0.4	402		 	 	0.9	85	9		 0.5909		 	0.0	210		 	 	0.1	03	4		 0.0968		 	0.4	174		 	 	0.9	90	1		KEGG_ASTHMA		 -0.9993		 0.0	000		 0.0	00	0		 0.0057		 0.9	727		 0.9	99	1		 0.4580		 0.2	233		 0.3	65	5		 0.0146		 0.9	282		 0.9	90	1		KEGG_ALLOGRAFT_REJECTION		 -1.0462		 0.0	000		 	0.0	00	0		 0.1173		 0.4	038		 0.9	85	9		 0.6057		 0.0	569		 0.1	53	3		 0.1261		 0.3	788		 0.9	90	1		KEGG_AUTOIMMUNE_THYROID_DISEA	SE		 	-1.0623		 	0.0	000		 	0.0	00	0		 0.0830		 	0.5	357		 	 	0.9	85	9		 0.6382		 	0.0	408		 	 	0.1	24	3		 0.0856		 	0.5	274		 	 	0.9	90	1		KEGG_INTESTINAL_IMMUNE_NETWOR	K_FOR_IGA_PRODUCTION		 	-1.2645		 	0.0	000		 	0.0	00	0		 -0.0217		 	0.8	626		 	 	0.9	85	9		 0.4684		 	0.1	186		 	 	0.2	34	6		 -0.0023		 	0.9	859		 	 	0.9	91	8		KEGG_PANTOTHENATE_AND_COA_BIO	SYNTHESIS		 	 	 	 -0.0035		 	 	 	 0.4184		 	 	 	 0.0268		 	 	 	
-1.3380				 0.0	000				 0.0	00	0				 0.9	670				 0.9	99	1			 		 0.0	275				 0.1	03	4			 		 0.7	322				 0.9	90	1			 		
Table	S2.	quSage	activity	scores	of	previously	idntified	APL-associated	signature	and	PPARG	transcriptional	targets			 	 	M3vsNonM3.KEGG		 ObVSNorm_All.KEGG		 ObVSNorm_M3.KEGG		 	 	ObVSNorm_nonM3.KEG	G		pathway.name		 log.fold.ch	ange		 p.Va	lue		 FDR		 log.fold.ch	ange		 p.Va	lue		 FDR		 log.fold.ch	ange		 p.Va	lue		 FDR		 log.fold.ch	ange		 p.Va	lue		 FDR		CASORELLI_ACUTE_PROMYEL	OCYTIC_LEUKEMIA_DN		 -0.4517		 0.00	00		 0.0	000		 -0.0506		 0.29	15		 0.9	995		 0.3199		 0.01	53		 0.0	972		 -0.0637		 0.16	90		 0.8	948		CASORELLI_ACUTE_PROMYEL	OCYTIC_LEUKEMIA_UP		 0.7557		 0.00	00		 0.0	000		 0.1166		 0.01	92		 0.9	995		 0.1573		 0.10	24		 0.2	172		 0.0723		 0.07	55		 0.8	948		LI_ADIPOGENESIS_BY_ACTIVA	TED_PPARG		 1.0578		 0.00	00		 0.0	000		 -0.0871		 0.47	97		 0.9	995		 -0.1286		 0.68	90		 0.7	617		 -0.1412		 0.24	97		 0.8	968		WANG_CLASSIC_ADIPOGENIC_	TARGETS_OF_PPARG				 	0.6578		 	0.00	00		 	 	0.0	000		 0.0057		 	0.94	87		 	0.9	995		 -0.1266		 0.28	91		 	0.4	158		 -0.0167		 0.84	42		 	 	0.9	787		
	
	
Table	S3.	Mutation	prevalences	in	obese	("OB")	and	non-obese	("NW")	patients	in	the	TCGA	dataset		ID		 OB_MUT		 NW_MU	T		 OB_WT		 NW_WT		 	OR		 CI_inf		 CI_sup		 fisher		 mLogPva	l		 FDR		 Sum_Mut		FLT3		 33		 22		 55		 88		 	2.4000		 1.2706		 4.5335		 0.0070		 4.9636		 0.1607		 55		NPM1		 23		 30		 65		 	 	80			 		 0.9436		 	0.5005				 	1.7791				 	0.8732				 	0.1355				 	1				 	53				DNMT3A		 20		 29		 68		 81		 0.8215		 0.4269		 1.5808		 0.6206		 0.4771		 1		 49		IDH2		 9		 11		 79		 99		 	1.0253		 0.4049		 2.5967		 1.0000		 0.0000		 1		 20		IDH1		 10		 9		 78		 	 	101			 		 1.4387		 	0.5577				 	3.7119				 	0.4757				 	0.7430				 	1				 	19				RUNX1		 7		 12		 81		 98		 0.7058		 0.2655		 1.8758		 0.6287		 0.4642		 1		 19		TET2		 7				 10				 81		 100		 	0.8642		 0.3150		 2.3712		 0.8052		 0.2167		 1		 17		TP53		 6		 10		 82		 100		 0.7317		 0.2552		 2.0981		 0.6100		 0.4943		 1		 16		
NRAS		 7		 8		 81		 	 	102		 1.1019		 	0.3835		 	3.1660		 	1.0000		 	0.0000		 	1		 	15		CEBPA		 6				 6				 82		 	 	104		 1.2683		 	0.3944		 	4.0783		 	0.7689		 	0.2628		 	1		 	12		WT1		 6		 6		 82		 104		 1.2683		 0.3944		 4.0783		 0.7689		 0.2628		 1		 12		PTPN11		 4				 5				 84		 	 	105		 1.0000		 	0.2604		 	3.8410		 	1.0000		 	0.0000		 	1		 	9		KIT		 5		 3		 83		 107		 2.1486		 0.4991		 9.2497		 0.4703		 0.7544		 1		 8		KRAS		 	3		 	5		 85		 105			 		 0.7412		 0.1722				 3.1903				 0.7348				 0.3081				 1				 8				U2AF1		 2		 6		 86		 104		 0.4031		 0.0793		 2.0483		 0.3037		 1.1916		 1		 8		STAG2		 	2		 	5		 86		 105		 0.4884		 0.0924		 2.5799		 0.4654		 0.7649		 1		 7		PHF6		 	1		 	5		 87		 105		 0.2414		 0.0277		 2.1051		 0.2291		 1.4735		 1		 6		ASXL1		 2		 3		 86		 107		 	0.8295		 0.1355		 5.0763		 1.0000		 0.0000		 1		 5		RAD21		 1		 4		 87		 	 	106			 		 0.3046		 	0.0334				 	2.7754				 	0.3843				 	0.9564				 	1				 	5				KDM6A		 2		 2		 86		 108		 1.2558		 0.1733		 9.0985		 1.0000		 0.0000		 1		 4		DIS3		 1		 2		 87		 108		 	0.6207				 0.0554		 6.9593		 1.0000		 0.0000		 1		 3		EZH2		 0		 3		 88		 107		 0.0000		 0.0000		 NA		 0.2555		 1.3645		 1		 3		SUZ12		 0		 3		 88		 	 	107		 0.0000				 	0.0000		 	NA		 	0.2555		 	1.3645		 	1		 	3			
